InsidersTradesSigma
Total declarations
Companies
▲ Purchases (5 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
5
Disclosed sells
5
T+90 hit rate
40%
T+90 mean return
-5.6%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Pauls Matthew, Director. Insider active across 4 companies, notably Pelthos Therapeutics Inc.. Cumulatively, 22 reports have been logged. Breakdown: 5 buys · 5 sells. Total volume traded: €443k. Activity tracked since 21 May 2021. The latest transaction was filed on 2 July 2026 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Pauls Matthew
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations22 total
692 shares@ US$25.99590.020% mcap87.5% of flowCommon StockSEC:0001919246-26-000101:0
94 shares@ US$27.36040.0029% mcap12.5% of flowCommon StockSEC:0001919246-26-000101:1
415 shares@ US$20.515422.9% of flowCommon StockSEC:0001919246-26-000053:0
371 shares@ US$21.362821.3% of flowCommon StockSEC:0001919246-26-000053:1
25,478 shares0Common StockSEC:0001919246-26-000042:0
195,705 shares@ US$6.9290.4% of flowCommon StockSEC:0001193125-25-321185:0
8,493 shares0Common StockSEC:0001753926-25-001884:0
23,629 shares0Common StockSEC:0001193125-25-316295:0
3,991 shares0Common StockSEC:0001415889-25-016358:0
5,937 shares@ US$4.60100.0% of flowCommon StockSEC:0001415889-25-009298:0
400,000 shares0Common StockSEC:0000950170-24-136782:0
6,500 shares0Common StockSEC:0001415889-24-016310:0
84,000 shares@ US$4.713139.0% of flowCommon StockSEC:0001209191-23-060009:0
109,680 shares@ US$4.4549.1% of flowCommon StockSEC:0001209191-23-058850:0
325,000 shares0Common StockSEC:0001209191-22-061411:0
62,318 shares@ US$1.240.0055% mcap50.4% of flowCommon StockSEC:0001209191-22-000131:0
400,000 shares0Common StockSEC:0001209191-21-069586:0
6,500 shares@ US$1.05990.0005% mcap4.5% of flowCommon StockSEC:0001209191-21-068494:0
Canonical exit: 8 Mar 2022 (T+90)
10,000 shares@ US$1.09540.0008% mcap7.1% of flowCommon StockSEC:0001209191-21-067432:0
Canonical exit: 2 Mar 2022 (T+90)
10,000 shares@ US$1.100.0008% mcap7.2% of flowCommon StockSEC:0001209191-21-066036:0
Canonical exit: 16 Feb 2022 (T+90)
15,000 shares@ US$1.181.2% of flowCommon StockSEC:0001209191-21-052200:0
Canonical exit: 15 Nov 2021 (T+90)
10,000 shares@ US$1.62981.0% of flowCommon StockSEC:0001209191-21-035163:0
Canonical exit: 19 Aug 2021 (T+90)
22 of 22 declarations
About Pauls Matthew
Pauls Matthew is Director and appears in 22 filings in total. In the 22 recent filings sampled, the cumulative amounts are EUR 53,950 in buys and EUR 388,633 in sells, with filings dated from 2021-05-24 to 2026-07-07, and the main filings concern Savara Inc, Soleno Therapeutics INC and Pelthos Therapeutics Inc.
